The process of breaking up research is dangerous one, according to UH's Big Idea. Graphic by Miguel Tovar/University of Houston

Salami slicing, breaking a paper on a single study up into smaller “slices” and publishing them in more than one journal, is broadly discouraged and considered unethical. Why does the practice persist? What do PIs believe are the benefits of doing it?

Two problems

Breaking up research into smaller slices can have serious consequences for scientific integrity. Researchers, especially younger researchers, may get used to looking at data in smaller pieces and not as a whole. This is dangerous from an academic perspective as valuable conclusions, that could have been derived if the data were presented as a whole, are overlooked.

Further, salami slicing of data may do more harm than good to a researcher’s career over time because it significantly reduces their chances of publishing in high impact journals, thereby lessening the weight of their accrued body of work.

One reason salami slicing still persists, is that there is a veritable avalanche of papers vying for publication. And the number seems to be steadily increasing.

“The academic market became more competitive after the nation’s economic downturn, in 2008,” said Rodica Damian, UH associate professor of psychology. “We saw a lot of competition between those with Ph.D.s and those who were conducting postdoc research. Before, you needed a postdoc if you were in Biology, for instance – but you didn’t need one if you had a doctorate in Psychology. That is no longer the case.”

Another reason salami slicing might persist is that advisors may suggest to a graduate student that they write a series of simpler papers as opposed to a more complex paper consisting of multiple measurements. A researcher might get these “single-lens papers” published much more quickly than their multi-faceted counterparts, due to the amount of background research the journal’s editors need to do on the more complicated papers.

How to avoid self-plagiarism

Salami slicing is not necessarily self-plagiarism, but often the practice does feature a large amount of “text overlap,” according to Miguel Roig, Ph.D. on the website of the Office of Research Integrity for the U.S. Department of Health and Human Services. One example Roig gives is as follows:

“Several months ago, for example, we received a manuscript describing a controlled intervention in a birthing center. The authors sent the results on the mothers to us, and the results on the infants to another journal. The two outcomes would have more appropriately been reported together…The important point is that readers need to be made aware that the data being reported were collected in the context of a larger study.”

The Big Idea

An article published by the NIH suggests this rule of thumb: “If the ‘slice’ of the study in question tests a different hypothesis as opposed to the larger study or has a distinct methodology or populations being studied, then it is acceptable to publish it separately.”

However, when a colleague is trying to do a meta analysis, they need to know what your study actually measured. “One thing you can do to avoid salami slicing,” said Damian, “is to pre-register all the projects you’re planning to do from a specific data set. Then ask yourself, do they use different hypotheses, measures, literatures, etc.”

After all is said and done, are they substantively methodically different research papers? If so, they can be sent to different, separate journals.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.